Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Trial Profile

Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs ALZ 801 (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Alzheon
  • Most Recent Events

    • 23 Jul 2018 Data from responder analyses of this trial presented in an Alzheon Media Release.
    • 23 Jul 2018 According to an Alzheon media release, data from patient responder analyses of this trial will be presented at 2018 Alzheimers Association International Conference.
    • 02 Nov 2017 According to an Alzheon media release, data will be presented at the 10th Annual Clinical Trials on Alzheimers Disease (CTAD) congress which will be held in 1-4 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top